12 Best Quality Stocks to Buy and Hold for the Next Decade
This article identifies Progyny, Inc. (NASDAQ: PGNY) as one of the best quality stocks for long-term investment, citing its strong market position in fertility benefits and impressive EPS growth projections. Analyst firms Truist and BofA have raised their price targets for Progyny, highlighting its differentiated services and favorable industry trends. The company's comprehensive approach and anticipated growth make it a compelling choice for investors looking for quality stocks to hold for the next decade.
How (PGNY) Movements Inform Risk Allocation Models
This article analyzes Progyny Inc. (NASDAQ: PGNY) using AI models to inform risk allocation. Key findings suggest strong near and mid-term sentiment, potential for upside, and the absence of clear price positioning signals. It outlines three institutional trading strategies tailored for different risk profiles: Position Trading, Momentum Breakout, and Risk Hedging, along with a multi-timeframe signal analysis.
Does Progyny’s (PGNY) Index Exit Quietly Recast Its Long‑Term Competitive Positioning?
Progyny's removal from the Russell 2000 Dynamic Index casts a new light on its long-term competitive positioning amid existing concerns over soft demand and limited cost leverage. This exit may add short-term trading pressure but doesn't fundamentally alter its near-term guidance or the risk of slower client adoption. Investors should consider Progyny's reliance on higher-value employer clients and its financial forecasts against this new development.
PGNY - Progyny Inc Volatility & Greeks
This article provides a detailed financial overview of Progyny Inc. (PGNY), including its volatility, key financial metrics, performance indicators, and market data. It covers various aspects like market capitalization, income, sales, P/E ratios, EPS, insider and institutional ownership, profitability margins, and stock performance over different periods. The data presented reflects the company's financial health and market position as of the last close on July 2nd, with a focus on its volatility and "Greeks" but without explicit values for options Greeks.
Does Progyny’s (PGNY) Index Exit Quietly Recast Its Long‑Term Competitive Positioning?
Progyny (PGNY) was recently removed from the Russell 2000 Dynamic Index, which could impact its investor perception and trading. This exit comes amidst existing concerns about soft demand and limited cost leverage, prompting questions about its long-term competitive standing. The article explores how this change could affect Progyny's investment narrative, especially in light of its 2026 guidance, and encourages investors to consider underlying fundamental challenges and opportunities.
Does Progyny’s (PGNY) Index Exit Quietly Recast Its Long‑Term Competitive Positioning?
Progyny (PGNY) was recently removed from the Russell 2000 Dynamic Index, which could affect how index-tracking funds manage the stock. This exit coincides with existing concerns about soft demand and limited cost leverage, prompting questions about the company's long-term competitive standing. Investors should consider how this index removal, coupled with Progyny's 2026 revenue and net income guidance, will influence the investment narrative and its appeal.
Progyny, Inc.(NasdaqGS: PGNY) dropped from Russell 2000 Dynamic Index
Progyny, Inc. (NasdaqGS: PGNY) has been removed from the Russell 2000 Dynamic Index. This news, published on June 29, 2026, details the company's current stock performance, recent analyst ratings, and its business profile as a benefit management company specializing in fertility and family building solutions.
Progyny stock hits 52-week high at 28.76 USD By Investing.com
Progyny Inc. (PGNY) stock reached a new 52-week high of $28.76, bringing its market capitalization to $2.24 billion. This rise is attributed to strong demand for its fertility benefits services and positive analyst revisions, with the stock appearing undervalued. The company recently reported strong Q1 results, exceeding analyst expectations, and announced a $200 million share repurchase program.
Progyny, Inc. Actuals & Estimates (NASDAQ:PGNY)
This article provides key financial data and analyst estimates for Progyny, Inc. (NASDAQ:PGNY), covering its stock price performance, forecasts, historical highs and lows, market capitalization, and earnings. It also includes information on the company's revenue, net income, employee count, EBITDA, and analyst ratings, presenting a comprehensive overview for potential investors.
PGNY Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Progyny, Inc. (PGNY) stock, based on analyst ratings and current market performance. It details the company's financial metrics, including EPS, revenue, net income, and market capitalization, along with its stock price history and volatility. The article also addresses frequently asked questions about investing in PGNY, its earnings reports, and future projections.
Price to sales forward of Progyny, Inc. – NASDAQ:PGNY
This article provides a brief financial overview of Progyny, Inc. (NASDAQ:PGNY), specifically focusing on its price to sales forward metric. It indicates that the market was closed at the time of publication and there were no trades. The content also lists various features and services offered by TradingView.
Price to book forward of Progyny, Inc. – BX:PGNY
This article provides the "Price to book forward" financial metric for Progyny, Inc. (BX:PGNY) on TradingView. It shows that the metric is presented for a specific period, including its value, change, and percentage change. The data is supplied by ICE Data Services and FactSet.
Enterprise value to revenue forward of Progyny, Inc. – NASDAQ:PGNY
This article provides financial information for Progyny, Inc. (NASDAQ: PGNY), focusing on its enterprise value to revenue forward. It appears to be a financial data point from TradingView, without further detailed analysis in the provided content.
What Does the Sale of Progyny Shares by the CFO Mean for Investors?
Progyny's CFO, Mark S. Livingston, sold 8,275 shares of the company's common stock, a transaction representing about 9.47% of his direct holdings. This sale, part of a pre-arranged Rule 10b5-1 trading plan adopted in August 2025, is not considered a red flag for investors despite the shares being on an upswing. The company is projecting strong revenue growth for 2026, indicating increased income from other customers despite losing a major client.
Progyny, Inc. Stock 12‑Month Price Target Raised to $30.4, Implies 13% Upside
Progyny, Inc.'s average 12-month price target has increased from $30 to $30.4, based on estimates from 10 analysts, with a range of $27 to $33 per share. This updated target suggests a potential upside of approximately 13% from the June 24 closing price. The consensus rating for Progyny remains a "Buy" from all 10 covering analysts.
Form 4 Progyny Inc For: 23 June By Investing.com
This article from Investing.com announces the filing of Form 4 for Progyny Inc. on June 23. It states that Progyny's stock symbol is PGNY and lists its performance with a 1.33% increase. The article itself simply serves as a brief notice of the financial filing.
Progyny (PGNY) Chief Product Officer has 819 shares withheld for RSU taxes
Progyny, Inc.'s Chief Product Officer, Geoffrey Clapp, had 819 shares of common stock withheld on June 17, 2026, to cover tax obligations related to the vesting of his restricted stock units. The shares were valued at $26.60 each for tax purposes, and this transaction was a routine tax-withholding disposition, not an open-market sale. Following this, Clapp directly holds 59,828 shares of Progyny common stock.
Progyny Inc (PGNY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Progyny Inc (PGNY), focusing on its business segments and regional contributions. For the fiscal year 2025, the company's revenue was primarily driven by fertility benefits services, accounting for 64.48%, and pharmacy benefits services at 35.52%. All of Progyny's reported revenue, totaling $1.29 billion, originated from the United States.
Progyny Inc (PGNY) Dividends & Stock Splits: Historical Payouts and Event Timeline
The article provides a financial overview of Progyny Inc (PGNY), focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and has no recorded stock split events. The page also includes current stock performance data, market capitalization, and P/E ratio for Progyny Inc.
Progyny Inc (PGNY) Financial Health: Profitability & Balance Sheet Analysis
This article analyzes the financial health of Progyny Inc (PGNY), highlighting its robust financial status and high operating efficiency. The company's financial score is 9.36, ranking it 3rd in the Healthcare Providers & Services industry. Progyny reported a 1.38% year-over-year increase in revenue to $328.50M and a 60.91% increase in net profit.
Progyny Inc (PGNY) Institutional Confidence
Progyny Inc (PGNY) has a high institutional confidence score of 10.00, ranking 1st in the Healthcare Providers & Services industry. The institutional shareholding proportion has increased to 113.05%, with ETHSX being the largest shareholder. Major institutional holders include BlackRock, Kleiner Perkins, and Fidelity Management, with several showing significant increases in their holdings.
Progyny Inc (PGNY) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Progyny Inc (PGNY), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. The analysis suggests that PGNY is suitable for range-bound swing trading, with a majority of indicators and all moving averages signaling a "Buy."
What Progyny (PGNY)'s Supermajority Rollback and US$200 Million Buyback Mean For Shareholders
Progyny (PGNY) recently secured shareholder approval to remove a supermajority voting requirement for certain business combinations and authorized a US$200 million share repurchase program. These moves enhance shareholder flexibility and signal management's confidence, but the company's investment narrative still hinges on employer demand for fertility benefits and the success of new client initiatives like Progyny Select, which targets small employers. Investors should consider these factors against the backdrop of potential benefit budget tightening and Progyny's long-term growth forecasts.
What Progyny (PGNY)'s Supermajority Rollback and US$200 Million Buyback Mean For Shareholders
Progyny, Inc. received shareholder approval to remove a supermajority voting requirement for certain business combinations and authorized a US$200 million share repurchase program. These actions aim to boost shareholder flexibility and demonstrate management's confidence in the company's financial health and future prospects. The article discusses how these changes, alongside its Progyny Select launch, could influence the company's investment narrative, particularly concerning employer demand for fertility benefits and its growth strategy.
What Progyny (PGNY)'s Governance Shift And $200 Million Buyback Mean For Shareholders
Progyny (PGNY) recently secured shareholder approval to remove a supermajority voting requirement for certain business combinations and initiated a new US$200 million share repurchase program, building on previous buybacks. These actions, alongside positive analyst commentary, signal management's confidence and an evolving approach to shareholder alignment. While the buyback program doesn't alter fundamental demand and competition risks in the fertility and women's health benefits market, it aims to soften share price volatility and concentrate ownership among remaining shareholders.
What Progyny (PGNY)'s Supermajority Rollback and US$200 Million Buyback Mean For Shareholders
Progyny, Inc. (PGNY) has approved a change to its Certificate of Incorporation, removing a supermajority voting requirement for certain business combinations, and authorized a US$200 million share repurchase program. These actions are intended to enhance shareholder voting flexibility and demonstrate management's confidence in the company's financial position and future prospects. The article discusses how these changes, alongside the launch of Progyny Select for small employers, might influence the company's investment narrative and risk profile, especially concerning employer demand for fertility benefits.
Progyny Inc stock (US74340E1038): fertility benefits specialist after recent share price swings
Progyny Inc. (PGNY) stock has experienced recent share price fluctuations, drawing investor attention to its role as a fertility benefits specialist. The company provides employer-sponsored fertility and family-building benefits in the US, focusing on managed care, curated clinic networks, and integrated pharmacy solutions. Its growth is driven by employer adoption and perceived value, though it remains sensitive to broader healthcare spending and labor market conditions.
Progyny (PGNY) Schedule 13G/A Amendment No.4 — Kleiner Perkins shows 0% ownership
Progyny, Inc. filed a Schedule 13G/A Amendment No. 4, indicating that Kleiner Perkins entities report zero beneficial ownership and 0% of the class. This amendment, signed by Susan Biglieri on June 5, 2026, is a routine ownership disclosure rather than a transaction notice, confirming that Kleiner Perkins holds no voting or dispositive power over PGNY shares.
Progyny (NASDAQ:PGNY) EVP Sells $15,022.92 in Stock
Progyny (NASDAQ:PGNY) Executive Vice President Allison Swartz sold 599 shares of company stock valued at approximately $15,022.92 on June 4th, with a previous sale of 1,199 shares on June 3rd. Following these transactions, Swartz still holds 82,378 shares. The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, and the company recently reported strong quarterly earnings, and initiated a $200 million share repurchase program.
Progyny CFO Mark Livingston sells $64,183 in company stock
Progyny's CFO, Mark Livingston, sold $64,183 worth of company stock through a Rule 10b5-1 trading plan. These sales occurred around the time 1,421 shares were withheld for tax payments related to restricted stock units. Despite the insider sale, Progyny reported strong first-quarter financial results and received upgraded ratings and price targets from analysts, indicating a positive outlook for the company.
Progyny CFO Mark Livingston sells $64,183 in company stock
Progyny's CFO, Mark S. Livingston, sold $64,183 worth of company stock at $25.50 per share through a pre-arranged trading plan, while also having shares withheld for taxes. Following these transactions, Livingston directly holds 74,688 shares. This comes amidst positive news for Progyny, including strong Q1 results, a share repurchase program, and analyst upgrades.
Progyny EVP Allison Swartz sells $45,021 in company stock
Progyny's EVP Allison Swartz sold $45,021 worth of company stock through a Rule 10b5-1 trading plan, in addition to shares withheld for tax obligations. Following these transactions, she directly holds 82,378 shares. This news comes as Progyny reported strong Q1 earnings, a new share repurchase program, and received upgraded ratings and price targets from analysts like Canaccord Genuity and Citizens.
Progyny (PGNY) CEO reports 5,361-share tax withholding, holds 811,472 shares
Progyny, Inc. CEO Peter Anevski reported a routine equity transaction where 5,361 shares of common stock were withheld at $25.12 per share to cover taxes upon the vesting of restricted stock units. Following this tax-withholding disposition, Anevski directly holds 811,472 shares, which includes 1,111 shares acquired through an Employee Stock Purchase Plan, and indirectly holds 1 additional share. The transaction was not an open-market sale, but a tax-related disposition denoted by transaction code F.
Progyny (PGNY) EVP Swartz logs small share sales under 10b5-1 plan
Progyny EVP and General Counsel Allison Swartz reported selling 1,798 shares of company common stock on June 3-4, 2026, at approximately $25 per share, as part of a pre-arranged Rule 10b5-1 trading plan. Additionally, 1,015 shares were disposed of to cover withholding taxes related to restricted stock unit vesting. Following these transactions, Swartz directly holds 82,378 shares of Progyny common stock.
Progyny (PGNY) CFO Livingston sells shares in 10b5-1 plan, retains 74,688
Progyny, Inc. CFO Mark S. Livingston sold 2,517 shares of common stock at $25.50 per share on June 4, 2026, as part of a pre-arranged Rule 10b5-1 trading plan. Additionally, 1,421 shares were withheld on June 3 and 4 to cover tax obligations from vested restricted stock units. Following these transactions, Livingston directly holds 74,688 shares of Progyny common stock.
PGNY (NASDAQ: PGNY) affiliate files Rule 144 reporting sales and vesting
Progyny, Inc. (NASDAQ: PGNY) has filed a Rule 144 notice disclosing sales and vesting of company stock by an affiliate. The filing indicates sales of 8,275 shares for $211,012.50 on May 20, 2026, and 279 shares for $7,309.80 on June 2, 2026. Additionally, the report notes restricted stock vesting of 1,918 shares on June 3, 2026, and 599 shares on June 4, 2026.
Progyny (PGNY) Authorizes $200M Share Repurchase Program
Progyny, Inc. (NASDAQ:PGNY) has announced a $200 million share repurchase program, approved by its Board of Directors to buy back common stock using available cash balances. This follows positive analyst upgrades from Canaccord and Barclays, citing improved guidance philosophy, beating quarterly estimates, and strong Q1 adjusted EPS and revenue figures. The company, which provides fertility and family-building benefits, is seen by analysts as positioned for future double-digit revenue growth.
Allison Swartz (PGNY) reports sales of 599, 2,398 and 1,199 shares
Allison Swartz, an insider at Progyny, Inc. (PGNY), reported dispositions of common stock through Rule 144 notices. The filing details three sales: 599 shares on March 4, 2026, 2,398 shares on May 28, 2026, and 1,199 shares on June 3, 2026, with associated dollar amounts for each transaction. The filing also mentions a "Restricted Stock Vesting" for 599 shares on June 4, 2026.
Conservative Guidance Weighed on Progyny (PGNY) Amid Strong Demand and Solid Execution
Voya Investment Management's "Voya MI Dynamic Small Cap Fund" highlighted Progyny, Inc. (NASDAQ:PGNY) in its first-quarter 2026 investor letter. Despite strong underlying demand and solid execution, conservative 2026 guidance and administrative reductions in covered lives negatively impacted investor sentiment and the stock's performance. The fund maintained an overweight position in Progyny based on its valuation and features like ROIC and buyback yield.
5 Most Promising Stocks to Buy Right Now
This article highlights Progyny, Inc. (NASDAQ: PGNY) as one of the most promising stocks currently. The company recently announced a $200 million share repurchase program and received "Buy" upgrades from analysts at Canaccord and Barclays due to strong Q1 earnings and positive outlooks. Progyny provides fertility, family-building, and women’s health benefits solutions in the United States.
Progyny (PGNY) CFO logs small share sale and tax withholding moves
Progyny, Inc.'s CFO, Mark S. Livingston, executed routine equity transactions, selling 279 shares under a pre-arranged Rule 10b5-1 trading plan and having 158 shares withheld for tax obligations related to restricted stock unit vesting. Both transactions occurred at $26.20 per share. Following these moves, Livingston's direct ownership of Progyny common stock stands at 78,626 shares.
Progyny (NASDAQ: PGNY) executive exercises options with small share sale
Progyny's Chief Product Officer, Geoffrey Clapp, engaged in several equity transactions. He exercised stock options to acquire 12,909 shares, sold 1,530 shares in an open-market transaction, and had 11,379 shares withheld for tax purposes related to restricted stock unit vesting. After these activities, Clapp directly holds 59,117 shares of Progyny common stock and 26,211 stock options.
Director at Progyny (NASDAQ: PGNY) exercises options and sells stock
Progyny director Scott Cheryl exercised stock options to acquire 14,667 shares at $13.00 each, then sold 7,439 shares in an open-market transaction for approximately $26.39 per share. The company withheld 7,228 shares to cover tax obligations. Following these transactions, Cheryl now directly holds 19,772 shares of Progyny common stock.
Allison Swartz (PGNY) files Form 144 to sell 1,199 vested shares (06/03/2026)
Allison Swartz has filed a Form 144 indicating a proposed sale of 1,199 shares of Progyny, Inc. (PGNY) common stock. These shares are tied to restricted stock vesting and will be sold through Fidelity Brokerage Services LLC on June 3, 2026, as compensation-related shares. The filing also notes previous dispositions by Swartz, including 4,657 shares on March 3, 2026; 599 shares on March 4, 2026; and 2,398 shares on May 28, 2026.
[144] Progyny, Inc. SEC Filing
This SEC filing details a Form 144 for Progyny, Inc. (PGNY), indicating a proposed sale of 1530 shares of common stock with an aggregate market value of $39,137.40. The securities were acquired on June 2, 2026, through a stock option exercise, and the transaction is facilitated by Fidelity Brokerage Services LLC. The filing shows no previous sales in the past three months and is dated June 2, 2026.
PGNY Maintained by B of A Securities -- Price Target Raised to $31
B of A Securities has maintained a "Buy" rating for Progyny (PGNY) and raised its price target to $31, signaling increased confidence in the company's future performance. GuruFocus indicates PGNY is undervalued by 8.7% with a strong GF Score of 91/100, driven by high growth and profitability. Investors should consider the recent insider selling activity alongside these positive indicators.
Jefferies cuts Progyny stock price target on guidance miss
Jefferies has lowered its price target for Progyny (NASDAQ:PGNY) to $30 from $36, while still maintaining a Buy rating, due to the company's fiscal 2026 guidance falling below Wall Street expectations and a corrective adjustment to its year-end member count. Despite the guidance miss, Jefferies noted that Progyny's fundamentals remain strong, with stable pricing and utilization rates, and continued double-digit new member additions. Other firms like BTIG, KeyBanc, and Truist Securities also adjusted their price targets downward, citing concerns over covered lives and EBITDA guidance, even though Progyny reported strong Q4 2025 earnings which surpassed forecasts.
Progyny, Inc. Stock 12‑Month Price Target Raised to $29.73, Implies 13% Upside
Progyny, Inc.'s average 12-month price target has been increased to $29.73, up from $29.55, based on estimates from 11 analysts. This new target suggests a 13% potential upside from the June 1 closing price. The consensus rating for the stock remains a "Buy" among the covering analysts.
Progyny (PGNY) EVP, GC Swartz sells shares under Rule 10b5-1 plan
Progyny's Executive Vice President and General Counsel, Allison Swartz, reported two transactions involving company common stock on May 28, 2026. She sold 2,398 shares at $25.46 each under a pre-established Rule 10b5-1 trading plan and had 1,352 shares withheld for tax purposes related to restricted stock unit vesting. After these transactions, Swartz directly owns 87,589 shares of Progyny common stock.
Director proposes sale of 2,676 shares — PGNY (NASDAQ: PGNY)
Progyny (NASDAQ: PGNY) director Cheryl Scott has filed a Form 144 notice proposing the sale of 2,676 shares of common stock, with a proposed sale date of June 1, 2026. The filing also notes a previous sale of the same number of shares on May 22, 2026, for $66,177.48. Fidelity Brokerage Services LLC is listed as the broker for the transaction, and the shares were acquired via an option granted on October 24, 2019.
